These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3325931)

  • 1. Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa.
    Haverkorn MJ
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S64-7. PubMed ID: 3325931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.
    Haverkorn MJ
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):661-4. PubMed ID: 3143577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
    Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
    Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
    Antonela Antoniu S
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.
    Hyatt JM; Schentag JJ
    Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S9-11. PubMed ID: 10654629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.
    Leigh DA; Emmanuel FX; Petch VJ
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():117-21. PubMed ID: 3542943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of pseudomonas infection in connection with chronic bronchitis. Therapeutic problems].
    Häusermann R; Gartmann J
    Schweiz Med Wochenschr; 1973 Nov; 103(44):1553-5. PubMed ID: 4491043
    [No Abstract]   [Full Text] [Related]  

  • 8. Experience with cefsulodin therapy for lower respiratory tract infections caused by Pseudomonas aeruginosa in adults without cystic fibrosis or granulocytopenia.
    Nichols L; Gudmundsson S; Maki DG
    Rev Infect Dis; 1984; 6 Suppl 3():S711-20. PubMed ID: 6443772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract].
    Chuchalin AG; Novikov IuK; Avdeev SN; Belevskiĭ AS
    Antibiot Khimioter; 1997; 42(6):34-8. PubMed ID: 9313057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
    Caplan DB; Buchanan CN
    Rev Infect Dis; 1984; 6 Suppl 3():S705-10. PubMed ID: 6443771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ciprofloxacin: an alternative oral treatment in respiratory Pseudomonas infection in cystic fibrosis].
    Magni A; Pradal U; Cazzola G; Mastella G
    Pediatr Med Chir; 1990; 12(5):531-4. PubMed ID: 2087426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
    Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
    Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients.
    Paull A; Morgan JR
    J Antimicrob Chemother; 1986 Nov; 18(5):635-9. PubMed ID: 3100487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin.
    Growcott EJ; Coulthard A; Amison R; Hardaker EL; Saxena V; Malt L; Jones P; Grevot A; Poll C; Osborne C; Banner KH
    J Cyst Fibros; 2011 May; 10(3):166-74. PubMed ID: 21247812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Follath F; Bindschedler M; Wenk M; Frei R; Stalder H; Reber H
    Eur J Clin Microbiol; 1986 Apr; 5(2):236-40. PubMed ID: 2941289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
    Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
    Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
    Kaye KS; Kanafani ZA; Dodds AE; Engemann JJ; Weber SG; Carmeli Y
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2192-6. PubMed ID: 16723582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Giamarellou H; Galanakis N; Dendrinos C; Stefanou J; Daphnis E; Daikos GK
    Eur J Clin Microbiol; 1986 Apr; 5(2):232-5. PubMed ID: 2941288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.